For the Quarter Ending September 2024
North America
In the third quarter of 2024, the pricing of Levocetirizine Dihydrochloride in North America experienced a consistent upward trajectory, influenced by various factors affecting market dynamics.
The increased demand for Levocetirizine Dihydrochloride was primarily driven by heightened consumer confidence and a positive economic outlook, leading to a surge in orders and overall market activity. Concurrently, supply chain disruptions, such as port congestion and delays, further constrained the availability of the product, putting upward pressure on prices. Importers and retailers proactively stockpiled inventory to guard against potential shortages, which also contributed to rising costs. Significant disruptions during the quarter included blank sailings and adverse weather conditions that affected logistics. In the USA, the market saw the most pronounced price fluctuations, mirroring the broader trend across North America. The quarter recorded a notable 2% increase in prices compared to the previous quarter, with a 1% price difference observed between the first and second halves of Q3.
Despite these challenges, the overall pricing environment remained favorable, culminating in a quarter-ending price of USD 537,500 per metric ton for Levocetirizine Dihydrochloride (USP, FDA) CFR Los Angeles. This figure underscores the complex interplay of demand dynamics and supply chain constraints impacting the market during this period.
Asia Pacific
In the third quarter of 2024, Levocetirizine Dihydrochloride prices in the APAC region experienced a notable uptrend, driven by several key factors. Robust demand from both domestic and international markets played a crucial role in driving prices higher. This surge in demand was fueled by increased inquiries from end-user industries and proactive stockpiling efforts by businesses in response to ongoing logistical uncertainties. These factors intensified the upward pressure on prices. Supply-side constraints also contributed significantly to the price surge. Production challenges and rising input costs further limited availability, making it difficult for suppliers to meet growing demand. China, in particular, saw the most pronounced price movements, reflecting the region's dynamic pricing environment. Despite a -2% decrease compared to the previous quarter, the overall pricing trend in Q3 showed a 1% increase between the first and second halves of the quarter, underscoring the bullish market sentiment. The quarter concluded with Levocetirizine Dihydrochloride (USP, FDA) priced at USD 513,000 per metric ton FOB Shanghai, highlighting the overall upward trajectory of the market, driven by a combination of strong demand, supply constraints, and positive market sentiment.
Europe
In Q3 2024, Levocetirizine Dihydrochloride prices in the European region experienced a notable upward trend, with Germany showing the most pronounced fluctuations. Several factors contributed to the pricing shifts throughout the quarter. One major influence was the ongoing disruptions in global maritime traffic, particularly in vital shipping routes, which led to delays, shortages, and elevated shipping costs. These logistical challenges placed considerable strain on the supply chain, limiting the availability of Levocetirizine Dihydrochloride. Additionally, strong demand from end-user industries, combined with companies stockpiling inventory to hedge against extended lead times, further pushed prices upward. In Germany, the market saw the most significant price variations, driven by both supply chain disruptions and heightened demand. The impact of seasonality was also evident, with a 2% price difference between the first and second halves of the quarter. Although there was a slight price dip compared to the previous quarter, the overall market sentiment remained positive. By the end of Q3, Levocetirizine Dihydrochloride (USP, FDA) CFR Hamburg was priced at USD 530,400 per metric ton, reflecting a challenging pricing environment shaped by increasing trends and ongoing supply chain obstacles.
For the Quarter Ending June 2024
North America
In Q2 2024, Levocetirizine Dihydrochloride pricing in North America experienced a mixed trajectory, reflecting diverse market dynamics. The quarter saw an initial increase in prices, followed by a mid-period decline, and a subsequent rise towards the end.
In April, prices rose due to a surge in domestic demand. Consumers, undeterred by cost fatigue, displayed a willingness to spend, leading to stronger retail sales and a higher demand for Levocetirizine Dihydrochloride. However, prices fell in the middle of the quarter as demand softened. The decrease in new orders and a contracting order backlog indicated a gradual economic slowdown. Additionally, the Federal Reserve's decision to maintain high interest rates, aimed at stabilizing inflation, inadvertently eroded consumer purchasing power, adding pressure to prices. Prices rebounded in June due to increased cargo import volumes at U.S. ports. Retailers ramped up stock levels to meet rising demand, especially as they approached the peak shipping season. This boost in import activity contributed to the upward trajectory in prices.
Overall, the price of Levocetirizine Dihydrochloride saw a notable -7% decline from the previous quarter, with a sharp -10% drop comparing the first and second halves of the quarter. The quarter ended with prices at USD 528,000 per metric ton CFR Los Angeles.
Asia Pacific
In Q2 2024, the Levocetirizine Dihydrochloride market in the APAC region exhibited fluctuating pricing trends. The quarter began with an increase in prices in April, driven by a boost in market confidence. Manufacturers in China capitalized on heightened demand by increasing production and inventory levels, reflecting a positive business outlook. However, prices fell in May as market sentiment weakened. Businesses faced challenges from diminishing consumer demand and growing financial pressures, impacting overall market conditions. In June, prices rebounded due to improved domestic demand and a rise in inquiries from key sectors such as pharmaceuticals and healthcare. The demand from international markets also remained strong, contributing to a steady increase in prices throughout the month. This uptick highlighted the resilience of the market amidst earlier challenges. Manufacturers faced rising input costs, largely due to escalating crude oil prices and increased prices for raw materials. These higher input costs were inevitably passed on to consumers in the form of higher Levocetirizine Dihydrochloride prices. Overall, the quarter demonstrated a varied pricing environment for Levocetirizine Dihydrochloride in the APAC region, marked by initial increases, a mid-period decline, and a final recovery.
Europe
In Q2 2024, the pricing landscape for Levocetirizine Dihydrochloride in Europe demonstrated a mixed trend influenced by various economic factors. In April, prices rose as the economy showed signs of improvement and consumer spending increased, driving up demand for Levocetirizine Dihydrochloride. This uptick in demand pushed prices higher. However, in May, prices declined due to a combination of factors. Companies faced dissatisfaction with business conditions, attributed to a lack of effective demand in the domestic market. Persistent inflationary pressures and high interest rates led to restrained consumer expenditure, with many sectors adopting a cautious "wait and see" approach. Additionally, currency appreciation reduced import costs for Levocetirizine Dihydrochloride, further contributing to the price decline. By June, prices rebounded as consumer sentiment improved for the fourth consecutive month, boosting domestic demand. The brighter economic outlook in Europe, particularly in its largest economy, supported the upward movement in prices. Overall, the quarter's pricing for Levocetirizine Dihydrochloride in Europe was characterized by initial increases, a mid-period decline, and a recovery towards the end of the quarter.
For the Quarter Ending March 2024
North America
In Q1 2024, the pricing dynamics of Levocetirizine Dihydrochloride in the North America region, particularly in the USA market, were shaped by a confluence of factors. Throughout the quarter, there was an evident decline in pricing, with significant attention paid to the interplay between supply and demand dynamics, market sentiment, and prevailing economic conditions. The USA market played a pivotal role in steering the pricing trend, as fluctuations were most pronounced within this region.
Consumer attitudes towards the economy adopted a notably cautious stance, reflecting a broader trend of uncertainty fueled by sluggish retail sales and subdued consumer spending. Moreover, the year-over-year price change from the same quarter last year underscored the tangible impact of economic uncertainties and inflationary pressures on Levocetirizine Dihydrochloride pricing. Similarly, the change from the last quarter of 2023 highlighted a clear downward trajectory in prices, driven by weakened demand and surplus supply. The market landscape portrayed an abundance of Levocetirizine Dihydrochloride supply, leading to reduced prices and heightened competition among market participants.
Consequently, the final quarter's price for Levocetirizine Dihydrochloride (USP, FDA) CFR Los Angeles in the USA was recorded at USD 587500/MT. This comprehensive analysis integrates various factors and insights, offering a sophisticated narrative on the pricing dynamics of Levocetirizine Dihydrochloride in Q1 2024.
Asia Pacific
During the first quarter of 2024, Levocetirizine Dihydrochloride prices in the APAC region, particularly in China, experienced a nuanced pricing dynamic influenced by various factors. While the top influences included reduced demand from downstream sectors, oversupply, and global economic slowdown, there were additional elements that shaped the pricing landscape. The availability of alternative options and generic versions of Levocetirizine Dihydrochloride contributed to decreased local demand, while the global demand for Chinese-manufactured goods declined due to elevated interest rates in major overseas markets. Additionally, disruptions in the global supply chain caused by tensions in the Red Sea affected exports from Asian countries, leading to an accumulation of pharmaceutical inventories and further impacting Levocetirizine Dihydrochloride prices. The ongoing challenges faced by China's manufacturing sector, characterized by a slow domestic recovery and subdued external demand, contributed to the overall downward trend in Levocetirizine Dihydrochloride prices. The combination of reduced demand, oversupply, and the closure of factories during the Lunar New Year period further contributed to the downward pressure on prices. The final quarter's price for Levocetirizine Dihydrochloride in China was stated as USD 560000 per MT, indicating a downward trend in pricing for the period.
Europe
In Q1 2024, the pricing dynamics of Levocetirizine Dihydrochloride in the Europe region exhibited a nuanced pattern influenced by multiple factors. While the overall trend indicated a decrease in prices, it is essential to consider the broader context. Germany, where price fluctuations were most pronounced, experienced a challenging market situation. Business sentiment declined, and consumer confidence waned, leading to diminished demand from the pharmaceutical and healthcare sectors. This, coupled with excess inventory due to stockpiling and a resurgence in inflation, contributed to the downward pressure on Levocetirizine Dihydrochloride prices. Compounding this situation was the decision of the central bank to maintain unchanged interest rates, placing an additional burden on consumers. In response to this stagnation, pharmaceutical companies opted to recalibrate their pricing strategies downward, aiming to stimulate purchasing activity and alleviate inventory burdens. Comparing Q1 2024 to the same quarter last year, Levocetirizine Dihydrochloride prices exhibited a decrease, reflecting the challenging market conditions. Moreover, when compared to the previous quarter, prices also showed a downward trend. Ultimately, the final price for Levocetirizine Dihydrochloride (USP, FDA) CFR Hamburg in Germany for Q1 2024 was USD 574500/MT.
For the Quarter Ending December 2023
North America
The fourth quarter of 2023 proved to be challenging for the Levocetirizine Dihydrochloride market in North America. The market experienced fluctuations in prices and supply due to various factors. Firstly, the market faced limited inventories, leading to a constrained supply of Levocetirizine Dihydrochloride. This was primarily caused by weakened trading activities with major exporting nations. Secondly, the demand for Levocetirizine Dihydrochloride remained moderate throughout the quarter, driven by consistent consumption in the healthcare and pharmaceutical sectors. Lastly, inflationary pressures and increased transportation costs contributed to an increase in prices.
The strength of the dollar against other currencies, such as the Chinese yuan, resulted in higher import costs, further impacting the pricing of Levocetirizine Dihydrochloride. In the USA, the largest market in North America, Levocetirizine Dihydrochloride prices experienced a marginal increase in the fourth quarter. Despite concerns about inflation and elevated prices, consumers displayed confidence in the US economy. The steady demand from end-users, particularly in the healthcare and pharmaceutical industries, contributed to the price stability. Additionally, the availability of Levocetirizine Dihydrochloride was maintained through effective inventory management practices.
Overall, the Levocetirizine Dihydrochloride market in North America faced challenges in the fourth quarter due to limited supply, moderate demand, and inflationary pressures. However, the USA market exhibited stability, driven by steady demand and adequate supply. The quarter ending price of Levocetirizine Dihydrochloride (USP, FDA) CFR Los Angeles in the USA was USD 597500/MT.
APAC
The fourth quarter of 2023 was characterized by stable pricing for Levocetirizine Dihydrochloride in the APAC region. The market witnessed limited supply, driven by disruptions in the supply chain and global uncertainties. However, the overall demand remained moderate, supported by the pharmaceutical and healthcare sectors. The manufacturing sector in China showed signs of recovery, with an expansion in factory activity and an increase in new orders. Despite challenges in export orders and lingering economic concerns, the Chinese economy displayed promising signs of stabilization. In China, Levocetirizine Dihydrochloride prices experienced a slight increase in October, followed by a more significant uptick in November. This can be attributed to improved market dynamics, including increased demand from end-users and improved consumer sentiment. Apart from that, the uptick in prices can be attributed to the onset of seasonal allergies, the cold and flu seasons, and other health-related trends, which positively influenced the overall market demand. The prices are expected to remain elevated in December, driven by sustained demand and an improved manufacturing sector. The price of Levocetirizine Dihydrochloride in China in the fourth quarter of 2023 is USD 570000 per MT (USP, FDA), FOB Shanghai.
Europe
In the fourth quarter of 2023, Levocetirizine Dihydrochloride pricing in Europe was influenced by several factors. Firstly, there was a scarcity of available stock in the market, which led to increased prices. Additionally, the high energy prices and transportation costs contributed to the price hikes. The demand for Levocetirizine Dihydrochloride remained moderate, driven by the ease of inflationary pressure and increased consumer confidence. Germany, in particular, experienced a significant impact on prices. The country saw a decrease in inflation, reaching its lowest level since the start of the Russia-Ukraine conflict. This reduction in inflation boosted consumer confidence and led to an increase in Levocetirizine Dihydrochloride prices. The price of Levocetirizine Dihydrochloride in Germany at the end of the quarter was USD 585500/MT (USP, FDA) CFR Hamburg. The price percentage change from the previous year's fourth quarter was -40%, indicating a significant decrease in prices. However, there was no change in prices from the previous quarter. The price comparison between the first and second half of the quarter showed no significant change.
For the Quarter Ending September 2023
North America
Prices for Levocetirizine Dihydrochloride increased in the United States during the third quarter. Prices grew by 0.44 percent in September compared to the previous month. In July, consumer confidence in the United States reached a two-year high, despite a persistently tight labor market and falling inflation. The Consumer Price Index increased by 3.2% year on year in July, up from 3% in June. Prices continued to grow in August, with gasoline and fuel oil prices rising by 9.1% and 10.6%, respectively, resulting in increased company expenses and shipping costs. Furthermore, factors such as rising warehousing prices, a scarcity of storage space, and inventory replenishment all contributed to this upward trend. Prices rose moderately in September as a result of rising inflation, sluggish trading activity, and continued demand from end-user industries. In the year ending September, the Consumer Price Index increased 3.7%, slightly more than the 3.6% projected. Energy costs rose 1.5%, with gasoline prices climbing 2.1% and fuel oil prices rising 8.5%. Furthermore, imports from China were slow, keeping Levocetirizine Dihydrochloride prices high.
Asia Pacific
Levocetirizine Dihydrochloride cost in China increased throughout the third quarter. Prices grew by 0.34 percent in September as compared to the previous month. According to the National Bureau of Statistics, China's consumer prices fell 0.3% year on year in July, while producer prices fell 4.4% year on year. This ease of inflation increased consumer confidence, resulting in increase in Levocetirizine Dihydrochloride pricing. In August, supply is constrained due to restricted industrial activity, resulting in fewer inventories among market manufacturers and traders. On the plus side, the rate of new orders increased over the previous month, causing the price of Levocetirizine Dihydrochloride to rise. Factory owners stated that producer prices had improved, and new orders had restarted increasing for the first time in five months. Furthermore, in September, China's manufacturing purchasing managers' index (PMI) elegantly climbed back into the expanding zone, revealing the restoration of industrial activity and signaling a promising economic revival within the country. On the demand side, there was a steady increase in new orders, showing that the manufacturing market is seeing persistent expansion.
Europe
During the third quarter, there was a notable rise in pricing for Levocetirizine Dihydrochloride in Germany. Prices grew by 0.53 percent in September compared to the previous month. According to the year-on-year (YoY) change in the consumer price index (CPI), inflation in Germany was 6.2 percent in July, compared to 6.4 percent in June. The reading indicated that inflation eased in July, putting consumer confidence on the positive side. Cost rose further in August due to elevated inflation, which was driven by increases in energy and oil prices, raising the expense of firms maintaining APIs (Active Pharmaceutical Ingredients). Levocetirizine Dihydrochloride prices rose further in September due to a lack of accessible stock, elevated energy prices, and rising end-user demand. Furthermore, the cost of air and maritime transportation increased significantly around the end of September, owing to China's annual holiday in October. This has also had an impact on the worldwide supply chain, resulting in an increase in Levocetirizine Dihydrochloride cost in Germany.
For the Quarter Ending June 2023
North America
The prices of Levocetirizine Dihydrochloride significantly declined by 9.44 percent in June from the levels noticed in April. The prices decreased due to several factors, such as surplus supply, lower APIs (Active pharmaceutical ingredients) prices, and decreased demand from domestic and foreign markets. China is the largest exporter of APIs to the United States. Due to the ease of COVID-19 restrictions, exports of levocetirizine dihydrochloride to the United States increased, increasing supply in the U.S. market and creating downward pressure on prices. In addition, inflation slowed in the second quarter due to the Federal Reserve's interest rate hikes, which subsequently reduced demand for Levocetirizine Dihydrochloride in the U.S. market, driving down prices. Additionally, the U.S. dollar appreciated against the Chinese yuan in June, making U.S. imports cheaper and increasing the availability of levocetirizine dihydrochloride, supporting the downtrend. Unfavorable market conditions persisted as market traders and suppliers were forced to cut prices to clear inventories due to weak end-user demand.
Asia Pacific
The prices of Levocetirizine Dihydrochloride declined by 7.89 percent in June compared to the levels seen in April. The factors responsible for this downward trend include ample supply and reduced demand from domestic as well as foreign markets. Chinese yuan weakened against the U.S. dollar, suggesting economic momentum in China remained on the weaker side, indicating a slowing down of the global economy, which added pressure on external demand from end-user industries. China's manufacturing PMI remained below 50 in the second quarter. According to the National Bureau of Statistics (NBS), PMI settled at 49 in June, compared to 48.8 in May and 49.2 in April, suggesting a contraction in manufacturing. This has slowed production due to weak consumer demand from the medical and pharmaceutical sectors, resulting in lower purchasing activity and fewer new orders, driving down the price of levocetirizine dihydrochloride. Meanwhile, the war in Ukraine continued to impact API supply chains, affecting exporting activity to other countries such as the U.S., leading to increased supplies in the Chinese market and resulting in a decline in levocetirizine dihydrochloride prices.
Europe
The prices of Levocetirizine Dihydrochloride decreased by 10.08 percent in June from the levels noticed in April. The factors responsible for this downward include weak purchasing activity and sufficient inventories in the German market. In Germany, the manufacturing PMI (Purchasing Managers' Index) has dropped to 41 in June 2023 from 43.2 in May and 44.5 in April, indicating the contraction in the manufacturing sector because of the aftermath of the COVID-19 pandemic. New orders have declined at a faster pace due to weakened demand from end consumers. The German economy has been hit by rising inflation and rising interest rates by European Central Bank, which has resulted in higher food and energy prices. This increased the cost of living and reduced consumer purchasing activity, further driving the downward trend in levocetirizine dihydrochloride prices. The appreciation of the euro against the U.S. dollar has made imports cheaper and has also increased the supply of levocetirizine dihydrochloride on the German market. This put downward pressure on the prices of levocetirizine dihydrochloride.
For the Quarter Ending March 2023
North America
Throughout the first quarter, the prices of Levocetirizine Di-Hydrochloride inclined in North America on account of a continuous surge in inquiries from the pharmaceutical and healthcare sectors. Moreover, Overall inflation eased with the start of 2023 and after a significant prolonged labor shortage, owing to which the businesses in the US increased employment in January, and wages rose. Following February, the prices continued to display a similar trend and were recorded at USD 658000/MT CFR Los Angeles. Towards the termination of Q1, as inquiries from the downstream sector continued to rise, Inventories for Levocetirizine Dihydrochloride API remained low among the market players, which compelled them to focus on raising their shelves.
APAC
In the APAC region, Levocetirizine Di-Hydrochloride prices, particularly in China, demonstrate an incremented trend throughout the first quarter of 2023. In the month of January, Levocetirizine Dihydrochloride prices inclined in China because of a significant surge in domestic and international inquiries. The values rose at the same rate as they depreciated in December. Ease in logistic charges and a continuous surge in demand further supported the positive price trend of Levocetirizine Di-hydrochloride during the month of February, and the costs noted during this month were assembled at USD 618500/MT FOB Shanghai in China. With the end of March, the prices remained in the northward direction, compelling the manufacturers to raise their production activity and procure their shelves with downstream Levocetirizine Di-hydrochloride stocks.
Europe
In the First quarter of 2023, the market for Levocetirizine Di-Hydrochloride in Europe followed a similar path to that in the Asia Pacific. The market trend began well until the end of March. During the month of February, the prices achieved an assembly price of USD 672000/MT CFR Hamburg in Germany. Compared to the previous quarter, the inquiries from the domestic market inclined at a steady rate. Market players further focused on building their inventories for Levocetirizine Dihydrochloride API to prevent their shortage. In addition to that, the trend for this API at the end of the first quarter was supported by higher trade flow and simpler logistic expenses when compared to the prior quarter.
For the Quarter Ending December 2022
North America
Over the first half of the fourth quarter, Levocetirizine Di-Hydrochloride's price gradually increased in North America. The pharmaceutical industry's end-user demand kept Levocetirizine Di-Hydrochloride costs on the high end. Additionally, there was a steep decline in supply chain disruption in the six months leading up to November across several measures, including shipping costs, which further bolstered the Levocetirizine Di-Hydrochloride market's upward trend. However, at the beginning of December, they started to fall precipitously due to a major decrease in their offtakes. Prices for Levocetirizine Di-Hydrochloride declined when they were recorded at USD 648000 /MT CFR Los Angeles.
APAC
In the fourth quarter of 2022, Levocetirizine Di-Hydrochloride prices in Asia, particularly in China, sharply declined. However, prices remained good throughout the initial half of q4 due to strong downstream demand balanced with supplies among market participants. On the other hand, the ease with which the supply chain was disrupted in November compared to October, including the lower shipping costs, encouraged the traders and suppliers to increase orders and balance the demand side. With the year 2022 concluding, China's production activities started to notably decline after November due to an increase in COVID-19 instances, which caused a decline in trade momentum and a reduction in freight costs, both of which helped the Levocetirizine Di-Hydrochloride price trend. Overall, the Levocetirizine Di-Hydrochloride costs noted in the middle of the fourth were assembled at USD 604500/MT FOB Shanghai in China.
Europe
The Levocetirizine Di-Hydrochloride market in Europe followed a similar trajectory to that in Asia Pacific in the fourth quarter of 2022. Due to a rise in demand from the end-user pharmaceutical business, the market trend started off well up until November and reached an assembly price of USD 663990/MT CFR Hamburg in Germany. Until December, Levocetirizine Di-Hydrochloride pricing inquiries from the downstream industry remained sturdy, reinforcing the drug's weaker price trend because market participants had plenty of supply and little demand. Furthermore, fresher orders did not require by traders as suppliers had enough stocks with them to meet any immediate necessities.
For the Quarter Ending September 2022
North America
In the North American region, Levocetirizine Dihydrochloride prices continued to decrease throughout the third quarter of 2022 due to weak demand from the downstream pharmaceutical sector. Additionally, adequate inventories in the domestic market have noticeably propelled Levocetirizine Dihydrochloride market sentiments to be on the lower side. Also, the zero covid policy in China has abrupted the global supply chain and negatively impacted the price trends of Levocetirizine Dihydrochloride in the United States. Trading activity witnessed from India also was on the dull side, which further supported the market sentiments of Levocetirizine Dihydrochloride in the North American region. Furthermore, towards the termination of Q3, the prices witnessed for Levocetirizine Dihydrochloride were settled at USD 147000/ MT CFR Los Angeles.
Asia Pacific
During the third quarter of 2022, the pricing trend for Levocetirizine Dihydrochloride in the Asia Pacific showed a fainter tendency. Consistent COVID-19 cases and strict lockdown conditions in China during August kept the market of Levocetirizine Dihydrochloride on the weaker side. Further, weak global demand with soaring energy prices declined the overall trading momentum, negatively affecting the pricing sentiments of Levocetirizine Dihydrochloride. Also, owing to fewer buying activities, domestic merchants were left with the stockpiling of downstream products propelling them to reduce the prices to destock their lists. With the ending of Q3, the price of Levocetirizine Dihydrochloride witnessed a decremented trend with the settlement of USD 129900/MT FOB Shanghai.
Europe
In the European region, the price of Levocetirizine Dihydrochloride witnessed a negative market sentiment backed by the weaker downstream demand and disrupted trading activities from the exporting countries. The war between Russia and Ukraine has affected the trading tendency throughout the region resulting in slowing commodities flow which negatively impacted the price trend for Levocetirizine in Europe. Throughout the whole Q3 of 2022, demand from end-user pharmaceutical companies remained dull. Overall, the providers had sufficient inventory to meet all domestic demand. Additionally, with the ending of Q3, the market witnessed a decremented trend owing to weaker demand and halted supplies from the APAC region. The prices demonstrated at the end of Q3 were settled at USD 149485/MT CFR Hamburg.
For the Quarter Ending June 2022
North America
The second quarter of 2022 showcased a declining trend in the prices of Levocetirizine Dihydrochloride in the North American market. The US market remained dull throughout the quarter as the downstream demand recorded were low. There were sufficient stocks with the traders in the market that could further fulfil the overall local demand. Lower fuel prices due to lessened import and export activities decreased freight rates and accumulated shipments which collectively impacted the market and Levocetirizine Dihydrochloride sodium prices in the region overall. Followed with the ending of q2 the price of Levocetirizine Dihydrochloride witnessed in North America region were assessed at USD 153000/MT CFR Los Angeles.
Asia-Pacific
In the Asia-Pacific region, the market prices of Levocetirizine Dihydrochloride remained on the lower edge during the second quarter of 2022. In the Indian market, the prices of Levocetirizine Dihydrochloride witnessed a fall as the manufacturers had enough product available to cater to the firm offtakes of the product from downstream sectors. The demand for antihistamine-producing pharmaceutical drugs remained slow in the Indian market, influencing the market prices. The need for products in China remained sluggish as the country remained silent throughout the quarter owing to the spread of infection. The production cost remained on the lower edge as the API prices remained stagnant. Towards the termination of q2 the prices inclined significantly owing to increased in downstream demand from end-user sectors. overall, the prices witnessed for Levocetirizine Dihydrochloride were settled at USD 122000/MT FOB Shanghai in China.
Europe
The European market witnessed a declined trend in the prices of Levocetirizine Dihydrochloride during the second quarter. The demand for antihistamine drugs remained weak in the region leading to low market prices of the product in the regional market. Furthermore, weaken query from customers resulted in a decrease transportation of the API from supplying countries which resulted in stockpiling of inventories at the ports. Weaken demand results in the stockpiled stocks with domestic suppliers due which they reduced the prices to destock their inventories. Also, Weak upstream Crude oil prices, regional demand resulted in the decreased prices of Levocetirizine Dihydrochloride in the market. Altogether, the prices recorded for Levocetirizine Dihydrochloride Di-hydrochloride were settled at USD 166650/MT CFR Hamburg in Germany.
